Caribou Biosciences Stock - Weekly review and sector backdrop

Caribou Biosciences stock gets a Friday checkup with a focus on this week’s moves, the broader gene-editing sector, and what the current analyst consensus signals for the CRISPR specialist.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 18:58 CET. Details in the imprint.

Caribou Biosciences (US1420381089) is ending the week without fresh company-specific headlines but remains part of an active gene-editing cohort on Nasdaq. The focus for Friday is a weekly review of the stock’s moves and its positioning versus peers.

How Caribou ended the week

Caribou Biosciences shares trade on Nasdaq under the ticker CRBU, alongside a cluster of clinical-stage gene-editing names. Public quote pages show a market capitalization clearly below $1 billion, underscoring the company’s early-stage profile in public markets.

The stock has recently moved in sympathy with broader biotech sentiment rather than company-specific headlines, reflecting investors’ shifting risk appetite for pre-commercial drug developers.

Peer performance and sector tone

Across the week, gene-editing peers such as CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics have seen mixed trading, with moves driven by macro factors and trial news rather than any single sector-wide catalyst, according to public market overviews.

Biotech as a whole has traded unevenly this week, mirroring broader risk-on and risk-off swings in U.S. stocks, as summarized in major market roundups that highlight healthcare and growth names among the more volatile segments.

What analysts focus on

Analyst coverage of Caribou remains centered on its lead allogeneic CAR-T candidate CB-010 and the broader pipeline, with consensus data providers classifying the company firmly as a high-risk, high-reward oncology play.

Broker commentary on the gene-editing space continues to emphasize clinical readouts, partnership potential with large pharma groups, and financing conditions as key drivers for valuations across the peer group, including Caribou.

The product behind the stock

Caribou Biosciences develops CRISPR-based genome-editing therapies, anchored by its lead product candidate CB-010, an allogeneic anti-CD19 CAR-T cell therapy targeting relapsed or refractory B-cell non-Hodgkin lymphoma.

Where the stock trades today

Caribou Biosciences shares (US1420381089) trade on Nasdaq at $4.50 as of 06/19/2026, 16:30 ET.

Key facts on Caribou Biosciences stock

• Company: Caribou Biosciences Inc.
• ISIN: US1420381089
• WKN: A2QJX2
• Ticker: CRBU
• Venue: Nasdaq
• Price (as of 06/19/2026, 16:30 ET): 4.50 USD
• Market cap: 400,000,000 USD (as of 06/19/2026)
• Sector / Industry: Health Care - Biotechnology
• Index membership: none of the major headline indices such as the S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.